Form 4: Beta Bionics CFO Sells Shares to Cover Tax Obligations

Beta Bionics, Inc.'s Chief Financial Officer, Stephen Feider, sold a total of 1,497 shares of common stock on June 2, 2025, to satisfy tax withholding obligations related to restricted stock unit vesting.

Summary

• Stephen Feider, the Chief Financial Officer of Beta Bionics, Inc. (BBNX), reported transactions on June 2, 2025.
• A total of 1,497 shares of Beta Bionics common stock were disposed of through three separate sales.
• The sales were conducted to cover tax withholding obligations associated with the vesting of restricted stock units.
• The shares were sold at weighted average prices of $17.028 (410 shares), $18.1489 (951 shares), and $18.691 (136 shares).
• Following these transactions, Mr. Feider directly beneficially owns 45,503 shares of common stock.

Sentiment

Score: 5

Explanation: The sentiment is neutral. The transaction is a routine, non-discretionary sale to cover tax obligations, which is a common practice for executives receiving equity compensation and does not typically signal a positive or negative outlook on the company's fundamentals.

Positives

• The sale of shares was explicitly stated to cover tax withholding obligations, indicating a non-discretionary transaction rather than a signal of lack of confidence in the company.

Negatives

• No inherently negative aspects are present, as the sale is for a routine tax-related purpose.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Management Comments

• The shares were sold to cover tax withholding obligations associated with the vesting of restricted stock units.

Industry Context

This filing represents a routine insider transaction, common across all industries, where executives sell a portion of vested equity awards to satisfy tax liabilities. It does not reflect a strategic shift or a change in the company's operational performance within the medical device or biotechnology industry.

Comparison to Industry Standards

• This type of transaction (sale-to-cover tax) is a standard practice for executives receiving equity compensation across all publicly traded companies, including those in the healthcare and technology sectors like Beta Bionics.
• There are no specific comparable companies or projects mentioned in this Form 4 to assess results against industry benchmarks, as it pertains solely to an individual's share ownership change.

Stakeholder Impact

• Shareholders: The sale represents a minor dilution of the CFO's direct ownership, but it is a routine tax-related event and not indicative of a change in company prospects. The overall impact on shareholders is negligible.
• Employees: No direct impact on employees is indicated by this filing.

Key Dates

Keywords

Beta Bionics, BBNX, Stephen Feider, CFO, Insider Trading, Form 4, SEC Filing, Stock Sale, Tax Withholding, Restricted Stock Units, Beneficial Ownership